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Spinal muscular atrophy treatment via targeting smn2 catalytic core
Abstract
The present invention is directed to methods and compositions for blocking the effect of the intronic
inhibitory splicing region of intron 7 of the SMN2 gene. The compositions and methods of the instant
invention include short oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target sites in the
SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed
transcript. The short target regions are 8-mers and 5-mers and also include the identification of a single
nucleotide base that is essential for initiating a long distance stearic inhibitory interactions as well as novel
targets distant from intron 7 which block the intronic inhibitory splicing of the same. These short target
regions and concomitant inhibitory blocking oligonucleotides are less expensive and easier to manufacture
and are small enough to cross the blood brain barrier.
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(57) ABSTRACT 
The present invention is directed to methods and composi 
tions for blocking the effect of the intronic inhibitory splicing 
region of intron 7 of the SMN2 gene. The compositions and 
methods of the instant invention include short oligonucle 
otide reagents (e.g., oligoribonucleotides) that effectively tar 
get sites in the SMN2 pre-mRNA, thereby modulating the 
splicing of SMN2 pre-mRNA to include exon 7 in the pro 
cessed transcript. The short target regions are 8-mers and 
5-mers and also include the identi?cation of a single nucle 
otide base that is essential for initiating a long distance stearic 
inhibitory interactions as well as novel targets distant from 
intron 7 which block the intronic inhibitory splicing of the 
same. These short target regions and concomitant inhibitory 
blocking oligonucleotides are less expensive and easier to 
manufacture and are small enough to cross the blood brain 
barrier. 
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SPINAL MUSCULAR ATROPHY TREATMENT 
VIA TARGETING SMN2 CATALYTIC CORE 
GRANT REFERENCE 
This invention was made with government support under 
NIH Grant No. 7 R01 NS055925 awarded by the United 
States National Institutes of Health. The government has 
certain rights in the invention. 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority under 35 U.S.C. §119 to 
provisional application Ser. No. 61/343,373 ?led Apr. 28, 
2010, herein incorporated by reference in its entirety. 
BACKGROUND OF THE INVENTION 
Alternative splicing increases the coding potential of 
human genome by producing multiple proteins from a single 
gene (Black, D. L. 2003. Annu Rev. Biochem. 72:291-336). It 
is also associated with a growing number of human diseases 
(Faustino, N. A., and T. A. Cooper. 2003. Genes Dev. 17:419 
437; Garcia-Blanco, M. A., et al. 2004. Nat. Biotechnol. 
22:535-546; Pagani, F., and F. E. Baralle. 2004. Nat. Rev. 
Genet. 51389-396). 
Spinal Muscular Atrophy (SMA) is an often-fatal genetic 
disorder resulting from the loss of the Survival Motor Neuron 
(SMN) protein encoded by the Survival Motor Neuron 
(SMN) gene. The SMN genes, SMN1 and SMN2, are located 
on chromosome 5 and SMA is caused by the loss of SMN1 
from both chromosomes. SMN2, while being almost identi 
cal to SMN1, is less effective at making the SMN protein. The 
severity of SMA is affected by the ef?ciency at which SMN2, 
of which there are several copies, produces the SMN protein. 
SMN1 encodes a ubiquitously expressed 38 kDa SMN 
protein that is necessary for snRNP assembly, an essential 
process for cell survival (Wan, L., et al. 2005. Mol. Cell. Biol. 
25:5543-5551). A nearly identical copy ofthe gene, SMN2, 
fails to compensate for the loss of SMN1 because of exon 7 
skipping, producing an unstable truncated protein, SMNA7 
(Lorson, C. L., et al. 1998. Nat. Genet. 19:63-66). SMN1 and 
SMN2 differ by a critical C to T substitution at position 6 of 
exon 7 (C6U in transcript of SMN2) (Lorson, C. L., et al. 
1999. Proc. Natl. Acad. Sci. USA 96:6307-6311; Monani, U. 
R., et al. 1999. Hum. Mol. Genet. 811177-1183). C6U does 
not change the coding sequence, but is suf?cient to cause 
exon 7 skipping in SMN1. 
Current treatment for SMA consists of prevention and 
management of the secondary effect of chronic motor unit 
loss. Currently, there are no drug therapies available for the 
treatment or prevention of SMA. 
Antisense technology, used mostly for RNA downregula 
tion, recently has been adapted to alter the splicing process 
(Kole et al., Acta Biochim Pol. (2004) 51, 373-8). Techniques 
that trick the splicing machinery to alter splicing of SMN2 
pre-mRNAs are likely to have high therapeutic value. 
SUMMARY OF THE INVENTION 
The present invention is based, in part, on the discovery 
that antisense targeting, displacement and/ or disruption of an 
intronic sequence in the SMN2 gene can enhance production 
of full-length SMN2 transcripts (transcripts containing exon 
7) during splicing. In particular, the present inventors have 
identi?ed critical regions of the intron 7 which must be 
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included to be work as a desirable therapeutic target. Accord 
ingly, the invention is directed to effective use of blocking 
agents, targeting this critical region. According to the inven 
tion, Applicants have identi?ed a short target comprising no 
more than 8 nucleotides which is effective as a therapeutic 
target. In another embodiment, Applicants have identi?ed a 
single critical base, 10C which must be targeted and which 
interacts with distant sequences in a stearic fashion to repair 
intron splicing. Quite surprisingly, Applicants have found that 
this critical base, and sequences 5' thereof, which do not 
include any previously known target motifs work better than 
any targets discovered to date, and create the opportunity to 
generate sequences as short as 5-mers that are effective in 
repairing splicing. The invention thus includes, blocking oli 
gonucleotide reagents (e.g., modi?ed antisense oligoribo 
nucleotides) to inhibit these critical intronic splice-inhibitory 
sequences. Treatment of cells derived from SMA patients 
with the oligonucleotide reagent compositions of the instant 
invention will effectively restore the production of the full 
length SMN protein. These results demonstrate for the ?rst 
time a stearic distant interaction between an oligonucleotide 
reagent and inhibition of an SMN2 splice site inhibitory 
domain. This distant interaction also provides a novel target 
site for inhibition of the intron 7 aberrant splicing and 
includes oligonucleotides designed to block a 10C interacting 
region of intron 7. 
Prior work by the inventors and others had discovered the 
ISS-N1, CCAGCAUUAUGAAAG (SEQ ID N011) an 
intronic element that harbors two putative hnRNP A1 binding 
sites (CAGCAU and UGAAAG) as a primary target for 
SMN2. Applicants here show that much shorter targets are 
effective, in fact even targets that do not include either of the 
hnRNP A1 site, and which include sequences which are 5' of 
the ISS-N1 target. 
The present invention therefore is directed to compositions 
capable of blocking the inhibitory effects of the newly-dis 
covered SMN2 shortened and critical intronic splice silenc 
ing domain. Agents capable of blocking the splice-inhibitory 
effect of this domain have high value as SMA therapeutics. 
Featured agents capable of blocking the splice-inhibitory 
effect of the SMN2 shortened domain include, but are not 
limited to, e.g., agents that disrupt the interaction of an target 
domain-interacting protein with the target sequence, agents 
that sequester a target interacting protein, agents that disrupt 
the structure of the target domain and/ or surrounding regions. 
In exemplary embodiments, the instant invention is 
directed to oligonucleotide reagents (e. g., modi?ed antisense 
oligoribonucleotides) that block the effect on pre-mRNA 
splicing of the SMN2 sequence via direct interaction and/or 
hybridization with the target sequence. Such RNA-comple 
mentary oligonucleotide reagents may be modi?ed by art 
recognized means to improve their in vivo stabilities and/or 
bioaccessibility. The instant invention also is directed to 
methods for identifying target domain-interacting proteins, 
as such methods are enabled by discovery and characteriza 
tion of the target sequence. 
In one aspect, the instant invention is directed to an isolated 
oligonucleotide reagent (e.g., an oligoribonucleotide) com 
prising a nucleotide sequence which is complementary to an 
SMN2 target comprising 8 bases or even surprisingly 5 or less 
bases in length and which also includes the critical loC base in 
the target sequence. These shorter oligonucleotides are easier 
and less expensive to manufacture and are small enough to 
cross the blood brain barrier, making them especially bene? 
cial for use therapeutics. 
US 8,802,642 B2 
3 
In another aspect, the instant invention is directed to an 
isolated oligonucleotide reagent (e.g., an oligoribonucle 
otide) Which is complementary to the 8mer sequence 
5'-CUGCCAGC-3'. 
In an additional aspect, the instant invention is directed to 
an isolated oligonucleotide reagent (e.g., an oligoribonucle 
otide) Which is complementary to the 5mer sequence 
5'-CUGCC-3'. 
In a further aspect, the instant invention is directed to an 
isolated oligonucleotide reagent (e.g., an oligoribonucle 
otide) Which is complementary to a sequence Which includes 
the 10C and sequence 5' thereof. 
In another aspect, the instant invention is directed to an 
isolated oligonucleotide reagent (e.g., an oligoribonucle 
otide) Which is greater than 90% complementary to the 
sequence 5'-5'-CUGCCAGC-3', or CUGCC. 
In an additional aspect, the instant invention is directed to 
an isolated oligonucleotide sequence comprising the 
sequence 5'-GCUGGCAG-3'. 
In another aspect, the instant invention is directed to an 
isolated oligonucleotide sequence comprising the sequence 
5'-GGCAG-3'. 
In another aspect, the instant invention is directed to an 
isolated oligonucleotide reagent comprising a sequence 
greater than 80% identical to the sequence 5'-GCUGGCAG 
3' or 5'-GGCAG-3'. 
In one embodiment, the oligonucleotide is modi?ed by the 
substitution of at least one nucleotide With a modi?ed nucle 
otide, such that in vivo stability is enhanced as compared to a 
corresponding unmodi?ed oligonucleotide. In a related 
embodiment, the modi?ed nucleotide is a sugar-modi?ed 
nucleotide. In another embodiment, the modi?ed nucleotide 
is a nucleobase-modi?ed nucleotide. 
In an additional embodiment, the modi?ed nucleotide is a 
2'-deoxy ribonucleotide. In certain embodiments, the 
2'-deoxy ribonucleotide is 2'-deoxy adenosine or 2'-deoxy 
guanosine. In another embodiment, the modi?ed nucleotide 
is a 2'-O-methyl (e.g., 2'-O-methylcytidine, 2'-O-methylp 
seudouridine, 2'-O-methylguanosine, 2'-O-methyluridine, 
2'-O-methyladenosine, 2'-O-methyl)ribonucleotide. In an 
additional embodiment, the modi?ed nucleotide is selected 
from the group consisting of a 2'-?uoro, 2'-amino and 2'-thio 
modi?ed ribonucleotide. In a further embodiment, the modi 
?ed nucleotide is selected from the group consisting of 
2'-?uoro-cytidine, 2'-?uoro-uridine, 2'-?uoro-adenosine, 
2'-?uoro-guanosine, 2'-amino-cytidine, 2'-amino-uridine, 
2'-amino-adenosine, 2'-amino-guanosine and 2'-amino-bu 
tyryl-pyrene-uridine. In an additional embodiment, the modi 
?ed nucleotide is selected from the group consisting of 
5-bromo-uridine, 5-iodo-uridine, 5-methyl-cytidine, ribo 
thymidine, 2-aminopurine, 5-?uoro-cytidine, and 5-?uoro 
uridine, 2,6-diaminopurine, 4-thio-uridine, and 5-amino-al 
lyl-uridine. 
In a further embodiment, the modi?ed nucleotide is a back 
bone-modi?ed nucleotide. In one embodiment, the back 
bone-modi?ed nucleotide contains a phosphorothioate 
group. In another embodiment, the modi?ed nucleotide is a 
locked nucleic acid (LNA). 
Another embodiment is directed to a composition compris 
ing an oligonucleotide of the invention. In certain embodi 
ments, the composition further comprises a pharmaceutical 
carrier. 
An additional embodiment of the invention is directed to a 
method of enhancing the level of exon 7-containing SMN2 
mRNA relative to exon-deleted SMN2 mRNA in a cell or cell 
extract, comprising contacting the cell or cell extract With an 
oligonucleotide (e.g., an oligoribonucleotide) of the inven 
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tion, such that the level of exon 7-containing SMN2 mRNA 
relative to exon-deleted SMN2 mRNA in the cell or cell 
extract is enhanced. In one embodiment, the cell or cell 
extract is a spinal muscular atrophy (SMA) patient-derived 
neuronal cell, muscle cell or ?broblast, or extract thereof. In 
certain embodiments, the cell or cell extract is selected from 
the group consisting of an embryonic stem cell, an embryonic 
stem cell extract, a neuronal stem cell and a neuronal stem cell 
extract. 
A related embodiment of the invention is directed to a 
method of enhancing the level of exon 7-containing SMN2 
mRNA relative to exon-deleted SMN2 mRNA in an organ 
ism, comprising administering to the organism an oligonucle 
otide of the invention (e. g., an oligoribonucleotide), such that 
the level of exon 7-containing SMN2 mRNA relative to exon 
deleted SMN2 mRNA in the organism is enhanced. In one 
embodiment, the organism is a mammal. In another embodi 
ment, the organism is a human. In certain embodiments, the 
human has spinal muscular atrophy (SMA). 
Another embodiment of the invention is directed to a 
method of treating spinal muscular atrophy (SMA) in a 
patient, comprising administering to the patient an oligo 
nucleotide of the invention (e.g., an oligoribonucleotide) in a 
dose effective to enhance the level of exon 7-containing 
SMN2 mRNA relative to exon-deleted SMN2 mRNA in cells 
of the patient, such that SMA in the patient is treated. 
A further embodiment is directed to a method for inhibiting 
an SMN2 pre-mRNA intronic splicing silencer site in a cell or 
cell extract comprising contacting the cell With an oligonucle 
otide of the invention (e. g., an oligoribonucleotide), such that 
the SMN2 intronic splicing silencer site is inhibited. In a 
related embodiment, the instant invention is directed to a 
method for inhibiting an SMN2 pre-mRNA intronic splicing 
silencer site in an organism comprising administering to the 
organism an oligonucleotide of the invention, such that the 
SMN2 intronic splicing silencer site is inhibited. Another 
embodiment is directed to a method for inhibiting an SMN2 
pre-mRNA intronic splicing silencer site in a subject With 
SMA comprising administering to the subject an oligonucle 
otide of the invention (e. g., an oligoribonucleotide), such that 
the SMN2 intronic splicing silencer site is inhibited. 
An additional aspect of the invention is directed to a 
method for identifying a protein that interacts With the 
sequences set forth as herein, SEQ ID NOS:2-5, comprising 
contacting a cell or cell extract With the sequence under 
conditions suf?cient for the sequence to interact With a pro 
tein in the cell or cell extract; and isolating the sequence and 
interacting protein, such that the protein that interacts With the 
target sequence is identi?ed. In one embodiment, the method 
further comprises UV-crosslinking the sequence to the inter 
acting protein. In an additional embodiment, the cell or cell 
extract is of mammalian origin. In certain embodiments, the 
cell or cell extract is of human origin. 
Another aspect of the invention is directed to a method of 
enhancing the level of exon 7-containing SMN2 mRNA rela 
tive to exon-deleted SMN2 mRNA in a cell or cell extract, 
comprising contacting the cell or cell extract With an oligo 
nucleotide or nucleotide targeted blocking agent of the inven 
tion, such that the level of exon 7-containing SMN2 mRNA 
relative to exon-deleted SMN2 mRNA in the cell or cell 
extract is enhanced. A related aspect of the invention is 
directed to a method of enhancing the level of exon 7-con 
taining SMN2 mRNA relative to exon-deleted SMN2 mRNA 
in an organism, comprising contacting the organism With an 
nucleotide SNM2 blocking agent, such that the level of exon 
7-containing SMN2 mRNA relative to exon-deleted SMN2 
mRNA in the organism is enhanced. 
US 8,802,642 B2 
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In one embodiment, the blocking agent is selected from the 
group consisting of a small molecule, a peptide, a polynucle 
otide, an antibody or biologically active portion thereof, a 
peptidomimetic, and a non-peptide oligomer. In an additional 
embodiment, the blocking agent is a small molecule. 
In an additional aspect, the invention is directed to a 
method of treating amyotrophic lateral sclerosis (ALS) in a 
patient, comprising administering to the patient the oligo 
nucleotide of the invention in a dose effective to enhance the 
level of exon 7-containing SMN2 mRNA relative to exon 
deleted SMN2 mRNA in cells of the patient. 
In an additional embodiment, the oligonucleotide reagent 
of the invention is a ribozyme. 
Other features and advantages of the invention will be 
apparent from the following detailed description and claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. An ultra-re?ned antisense micro-walk reveals the 
signi?cance of a cytosine residue at the 10th position (10C) of 
SMN2 exon 7. (A) Diagrammatic representation of cis-ele 
ments at the 5' end ofSMN2 intron 7 (SEQ ID NO:2). ISS-Nl 
(SEQ ID NO:l) is highlighted in yellow with all but the ?rst 
nucleotide shown in red. Two hnRNPAl motifs are indicated 
as described in (Hua et al. 2008). GC-rich sequence is high 
lighted in green (Singh et al. 2009). Numbering of nucle 
otides starts from the ?rst position of SMN2 intron 7. The 
location of 10C is marked by an arrow. (B) Diagrammatic 
representation of ASOs and their annealing positions relative 
to ISS-Nl region. Numbering of nucleotides starts from the 
?rst position of intron 7. Boundaries of ISS-Nl are demar 
cated. The ?rst ISS-Nl residue, 10C, is highlighted in blue. 
The GC-rich sequence (Singh et al. 2009) is highlighted in 
green. 
The core sequence of the antisense target is highlighted in 
yellow. ASOs are shown as horizontal bars. Green bars rep 
resent ASOs that promote SMN2 exon 7 inclusion (exon 7 
skipping is 45% and less). The intensity of green color re?ects 
the strength of ASO stimulatory effect. Grey bars represent 
ASOs that have no effect on SMN2 exon 7 inclusion. Pink 
bars represent ASOs that promoted SMN2 exon 7 skipping 
(exon 7 skipping is 55% and more). To emphasize that L14 
caused the most dramatic increase in exon 7 skipping, it is 
shown as a dark pink bar. (C) Splicing pattern of endogenous 
SMN2 after treatment with ASOs shown in panel B. SMA 
type I patient ?broblasts (GM03813) were treated with 20 nM 
of different ASOs and the total RNA for in vivo splicing assay 
was isolated 24 h post transfection. The upper band corre 
sponds to exon 7-included product; the lower band corre 
sponds to exon 7-skipped product. The percentage of exon 
skipping was calculated from the total value of exon-included 
and exon-skipped products. The values represent mean of 
three independent experiments. The standard deviations were 
less than 5% of mean. The effect of F14 and L14 are high 
lighted with green and red box, respectively. (D) Splicing 
pattern of endogenous SMN2 after treatment with 50 nM of 
indicatedASOs. The chemistry of the ASOs used is shown on 
the right. In vivo splicing assays were performed and ana 
lyzed as described in panel C. The values represent mean of 
three independent experiments. The standard deviations were 
less than 5% of mean. 
FIG. 2. Effect of ASOs are speci?c to their targets. (A) 
Diagrammatic representation of the target area in intron 7 of 
SMN2 minigene (SEQ ID NO:2). ISS-Nl is highlighted in 
light gray. Numbering of nucleotides starts from the ?rst 
position of intron 7. The location of 10C is marked by an 
arrow. The sequences of four ASOs (F14, SEQ ID NO:l2; 
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L14, SEQ ID NOzl3; Fl4comp, SEQ ID NO:22; Ll4comp, 
SEQ ID NO:23) and their annealing positions in ISS-Nl 
region are shown. Mutations are indicated in white letters and 
highlighted in black. Effect of ASOs on splicing of SMN2 
minigene is shown on the right. HeLa cells were co-trans 
fected with 50 nM of a given ASO and 0.1 pg of SMN2 
minigene. Splicing was determined 24 h after transfection. 
The percentage of exon 7 skipping was calculated as 
described in FIG. 1C. (B) Diagrammatic representation of the 
target area in intron 7 of SMN2/ 17-08 minigene (SEQ ID 
NO:64). ISS-Nl is highlighted in gray. Numbering of nucle 
otides starts from the ?rst position ofintron 7. Location of 10C 
is marked by an arrow. Sequences of four ASOs and their 
annealing positions are shown. Mutations in ISS-Nl area as 
well as in the ASOs are indicated in white letters and high 
lighted in black. Effect of theASOs on splicing of SMN2/l7 
08 minigene is shown on the right. In vivo splicing assays 
were performed and analyzed as described in panel A. 
FIG. 3. Sequestration of 10C decides the outcome of anti 
sense response. Numbering of nucleotides starts from the ?rst 
intronic position. ISS-Nl sequence is highlighted in grey. The 
?rst C residue in ISS-Nl is marked as 10C. (A) Diagrammatic 
representation of the 5' portion of intron 7 of SMN2 minigene 
(SEQ ID N012) and its mutant, SMN2/A64 (SEQ ID NO:65). 
The location of 10C and its deletion are indicated. Effect of 
ASOs on splicing of wild type and mutated SMN2 minigene 
is shown on the right. Co-transfections and analyses were 
done as in (FIG. 2A). (B) Diagrammatic representation of 
wild type and mutated ISS-Nl targeted by different ASOs. 
Sequences of ASOs and their base pairing with the corre 
sponding target are shown. F15 (SEQ ID NO: 5); F14 (SEQ ID 
NO:l2); L14 (SEQ ID NO:lS); lDN15 (SEQ ID NO:9); 
5'lU-Fl 5 (SEQ ID NO:66). Note that wild type and mutated 
ISS-Nl element are located within intron 7 of SMN2 and 
SMN2/64A minigene, respectively. Arrows mark 10C and 
10A positions. The 3'-overhang of ASOs are highlighted. 
Effect of ASOs on splicing of SMN2 minigene and its mutant, 
SMN2/64A, is shown in the bottom panel. Co-transfections 
and splicing analyses were done as in (FIG. 2A). 
FIG. 4. Effect of the local context on antisense response of 
ISS-Nl -targeting ASOs. (A) Diagrammatic representation of 
the target area in intron 7 of SMN2 minigene (SEQ ID 
NO:67) and its four mutants. ISS-Nl is highlighted in grey. 
The ?rst C residue in ISS-Nl is marked as 10C or 15 C depend 
ing on its position relative to the beginning of intron 7. Of 
note, numbering of intronic residues starts with the ?rst posi 
tion of intron 7. Five-nucleotide-long insertions immediately 
upstream ofISS-Nl in SMN2/5A (SEQ ID NO: 68) or SMN2/ 
5G (SEQ ID NO:69) minigenes are boxed and shown in 
capital letters. N1A30-34 (SEQ ID NO:70); N1A25-34 (SEQ 
ID NO:7l). (B) In vivo splicing pattern of wild type and 
mutant SMN2 minigenes shown in panel A. The minigenes 
were co-transfected with anASO of interest. Co-transfections 
and splicing analysis were done similarly as in (FIG. 2A). 
FIG. 5. Effect of the heterologous context on antisense 
response of ISS-Nl-targeting ASOs. (A) Diagrammatic rep 
resentation of exon 6/intron 6 junction in Casp3 minigene 
variants. 3'-Cluster and ISS-Nl, which are shaded in grey, 
were inserted either individually or together 3-nucleotide 
upstream and 9-nucleotide downstream of the exon/intron 
junction, respectively. Casp3-Avr (SEQ ID NO:72); Casp3 
3'Cl (SEQ ID NO:73); Casp3ISS-Nl (SEQ ID NO:74); 
CasleCl (SEQ ID NO:75). In Casp3-SMN5'-l (SEQ ID 
NO:76) minigene the entire region from the beginning of 
3'-Cluster to the end of ISS-Nl corresponds to SMN 
sequence. The last three nucleotides of SMN exon 7 and the 
?rst nine nucleotides of SMN intron 7 are highlighted in 
US 8,802,642 B2 
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black. As a result of this insertion, Casp3 exon 6 now has the 
5' ss of SMN exon 7 followed by ISS-N1 element. The loca 
tion of 10C is marked by an arrow. (B) Effect of 3'-Cluster and 
ISS-N1 insertions on Casp3 exon 6 splicing. HeLa cells were 
transfected with 0.8 pg of Casp3 minigene variant and the 
total RNA for in vivo splicing assay was isolated 24 h post 
transfection. Exon 6-included and exon 6-skipped spliced 
products are indicated. Percentage of exon skipping was cal 
culated from the total value of exon-included and exon 
skipped products similarly as in FIG. 2. (C) In vivo splicing 
patterns of two Casp3 minigene variants in the presence of 
ASOs. Co-transfections and splicing analysis were done as in 
FIG. 2A. (D) In vivo splicing patterns of Casp3SMN2 mini 
gene in the presence of ASOs. Diagram explaining the com 
position of this hybrid minigene is shown on the top. Co 
transfections and splicing analysis were done as in panel C. 
FIG. 6. Effect of deletions within intron 6 and intron 7 on 
antisense response of ISS-N1 -targeting ASOs. (A) Diagram 
matic representation of the deleted regions in intron 6 and 7 of 
SMN2 minigene. Deletions are represented by dotted lines. 
Positive numbers indicate nucleotide positions within intron 
7 and start from the ?rst position of this intron. Negative 
numbers indicate nucleotide positions within intron 6 and 
start from the last position of this intron. Names of mutants 
are given on the left; numbers in names re?ect positions of the 
?rst and the last deleted nucleotides. A deletion mutant pro 
ducing a stimulatory effect in presence of anASO is shown as 
plus, whereas a mutant producing a negative effect in pres 
ence of anASO is shown as minus. (B) In vivo splicing pattern 
of wild type and mutant SMN2 minigenes shown in panel A. 
Minigenes were co-transfected with an ASO of interest. Co 
transfections and splicing analyses were done similarly as in 
FIG. 2A. 
FIG. 7. Effect of deletions within intron 7 on antisense 
response of ISS-N1-targeting ASOs. (A) Diagrammatic rep 
resentation of the deleted regions within intron 7 of SMN2 
mini gene. Deletions are represented by dotted lines. Numbers 
indicate nucleotide positions and start from the ?rst position 
of intron 7. Names of mutants are given on the left; numbers 
in the names re?ect positions of the ?rst and the last deleted 
nucleotides.A deletion mutant producing a stimulatory effect 
in presence of an ASO is shown as plus, whereas a mutant 
producing a negative effect in presence of anASO is shown as 
minus. (B) In vivo splicing pattern of mutant SMN2 mini 
genes shown in panel A. Minigenes were co-transfected with 
an ASO of interest. Co-transfections and splicing analysis 
were done similarly as in FIG. 2A. 
FIG. 8. Site-speci?c UV-crosslinking of puri?ed recombi 
nant hnRNPA1 with ISS-N1 . (A) Puri?cation of recombinant 
hnRNP A1 protein expressed from pTXB3-A1 in E. coli 
ER2566 strain. Protein was puri?ed by binding to a chitin 
a?inity column, followed by DTT-induced self-cleavage of 
the Mycobaclerium xenopi GyrA intein. Sample aliquots 
were collected at different puri?cation steps and used for 
SDS-polyacrylamide gel electrophoresis. Lane 1, molecular 
weight markers; lane 2, clari?ed lysate; lane 3, ?ow through 
from the column; lanes 4 & 5, wash with increasing concen 
tration of NaCl; lane 6, DTT ?ush; lane 7, pooled hnRNP 
A1-containing fractions eluted after overnight DTT-induced 
intein self-cleavage at 4° C. Band corresponding to hnRNP 
A1 is indicated by an arrow. Right panel shows the diagram 
matic representation of pTXB3-A1 construct. This construct 
contains hnRNP A1 0RF with a C-terminus fused in frame to 
the Mycobaclerium xenopi GyrA intein/chitin binding 
domain (CBD). (B) Diagrammatic representation of steps for 
site-speci?c 32P-labeling of RNA probe. The sequence of 
probe and its relative location within SMN are given. 3' half 
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RNA (SEQ ID N0:31); 5' half RNA (SEQ ID N0:32). ISS 
N1 is highlighted in yellow and its sequence shown in red 
letters. Position of the 32P-radioisotope incorporation is indi 
cated by a star. The sequence of the bridging DNA oligo 
nucleotide (SEQ ID N0:33) is shown in green. (C) Autorad 
iogram showing hnRNP A1-crosslinked product. Site 
speci?cally 32P-labeled RNA probe was UV-crosslinked with 
puri?ed recombinant hnRNP A1 followed by RNase diges 
tion and fractionation on 13% SDS-polyacrylamide gel. (D) 
UV-crosslinking in the presence of different ASOs under 
“denaturing” condition. Here, RNA probe was ?rst refolded 
in the presence of a corresponding ASO to insure ASO 
annealing. After that the puri?ed hnRNP Al was added to the 
reaction mixture followed by UV-crosslinking Analysis of 
hnRNP A1-crosslinked products was done as in panel C. (E) 
UV-crosslinking in the presence of different ASOs under 
“native” condition. Here the RNA probe was denatured and 
refolded prior to an ASO and hnRNP A1 addition to the 
reaction mixture. UV-crosslinking reaction and analysis of 
the products were performed as in panel C. 
FIG. 9. Model of SMN2 exon 7 splicing modulation by 10C 
in the presence ofL14 and F14. (A) L14 Pathway: L14 leaves 
loC unsequestered and accessible for a long-distance interac 
tion with intronic sequences upstream of the branch point. 
This arrangement interferes with the catalytic core formation 
at the 5' ss of exon 7. Consequently, the competing 5' ss of 
exon 6 becomes the favorable substrate for the transesteri? 
cation reaction leading to exon 7 skipping. (B) F14 Pathway: 
F14 sequesters 10C and prevents a long-distance interaction 
with intronic sequences upstream of the branch point. This 
arrangement favors catalytic core formation at the 5' ss of 
exon 7. Consequently, SMN2 exon 7 inclusion is promoted. 
FIG. 10 is a diagram showing intron 7 and the long distance 
target sites for additional oligos. Long distance target 2 
(LDT2) (SEQ ID NO:3); TRGT16GC (SEQ ID NO:62). 
FIG. 11. Ultra-re?ned antisense microwalk to identify the 
shortest stimulatory ASO. (A) Diagrammatic representation 
of ASOs targeting sequences upstream of ISS-N1. Exon 7 is 
boxed and the ?rst 24 residues of human SMN intron 7 (SEQ 
ID N012) are shown. Numbering starts from the ?rst position 
of intron 7. The 5' ss of exon 7 is indicated by a vertical arrow. 
ASOs blocking different regions are shown as horizontal 
bars. Sequences of these ASOs are given in Table A. Bound 
ary of ISS-N1 (SEQ ID N011) is demarcated. hnRNP A1 
motifs are indicated. Green bars represent ASOs that promote 
SMN2 exon 7 inclusion. Intensity of green color re?ects the 
strength of stimulatory effect. Tan bars represent ASOs that 
have no effect on SMN2 exon 7 inclusion. Area highlighted in 
pink represents the only GC-rich sequence in the ?rst half of 
human intron 7. Area highlighted in light blue represents the 
core sequence of the antisense target. Right panel shows the 
relative positioning of ISS-N1, GC-rich sequence in the con 
text of predicted RNA structure. Green bar represents 3UP8, 
the shortest ASO to stimulate SMN2 exon 7 inclusion. (B) 
Splicing pattern of endogenous SMN2 in SMA type I patient 
?broblasts (GM03183) treated with different ASOs. Cells 
were transfected with 20 nM of 20MePS ASOs and the total 
RNA for splicing assay was isolated 24 h post transfection. 
Results were analyzed as described earlier. 3UP8 was the 
shortest ASO to show stimulatory response (highlighted by 
green box). 
FIG. 12. Antisense effect is speci?c to its target sequence. 
(A) Diagrammatic representation of intron 7 of SMN2 mini 
gene (SEQ ID N0:2) and its mutant, SMN2/ 64A (SEQ ID 
N0:77). Numbering starts from the ?rst position of human 
SMN intron 7. ISS-N1 sequence is highlighted in gray. 
Mutated residue is highlighted in black. (B) Effect of ASOs 








































